Compare · BSX vs SIBN
BSX vs SIBN
Side-by-side comparison of Boston Scientific Corporation (BSX) and SI-BONE Inc. (SIBN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SIBN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.39B, about 109.0x SIBN ($663.9M).
- Over the past year, BSX is down 51.3% and SIBN is down 20.6% - SIBN leads by 30.7 points.
- BSX has been more active in the news (12 items in the past 4 weeks vs 11 for SIBN).
- BSX has more recent analyst coverage (25 ratings vs 11 for SIBN).
- Company
- Boston Scientific Corporation
- SI-BONE Inc.
- Price
- $48.71+0.31%
- $14.97-1.12%
- Market cap
- $72.39B
- $663.9M
- 1M return
- -13.91%
- +15.60%
- 1Y return
- -51.31%
- -20.63%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 12
- 11
- Recent ratings
- 25
- 11
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
SI-BONE Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest SIBN
- Director Dunn Jeffrey W was granted 10,957 shares and sold $54,505 worth of shares (3,575 units at $15.25), increasing direct ownership by 75% to 16,057 units (SEC Form 4) to cover withholding tax
- Director Nishimura Mika was granted 10,957 shares, increasing direct ownership by 33% to 43,673 units (SEC Form 4)
- Director West Thomas A. was granted 10,957 shares, increasing direct ownership by 41% to 37,947 units (SEC Form 4)
- Director Freund John Gordon was granted 10,957 shares, increasing direct ownership by 25% to 54,258 units (SEC Form 4)
- Director Davis Timothy E Jr was granted 10,957 shares, increasing direct ownership by 17% to 76,679 units (SEC Form 4)
- SI-BONE Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
- Director Davis Timothy E Jr exercised 12,064 shares at a strike of $4.32 and sold $104,187 worth of shares (7,280 units at $14.31), increasing direct ownership by 8% to 65,722 units (SEC Form 4)
- Chief Executive Officer Francis Laura sold $220,000 worth of shares (14,957 units at $14.71), decreasing direct ownership by 8% to 503,444 units (SEC Form 4) to cover withholding tax
- SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. sold $54,527 worth of shares (3,726 units at $14.63), decreasing direct ownership by 0.82% to 280,509 units (SEC Form 4) (tax liability)